Pharmacoepidemiology is the study of intended and unintended effects of treatments and is therefore a fundamental component of clinical epidemiology. Pharmacoepidemiology provides post-approval evidence about benefit-risk profiles of treatments in broad patient populations, including vulnerable subgroups such as elderly patients, patients with comorbidities, or pregnant women. Pharmacoepidemiologic research is a key contributor to evidence-based medicine.
Pharmacoepidemiology research at Department of Clinical Epidemiology is closely interwoven with our other research areas and clinical expertise. The research focuses on associations between use of medication and procedures in relation to outcomes of chronic and acute conditions. Our current projects examine the use of medications in relation to outcomes of infectious diseases, cardiovascular diseases, diabetes, osteoporosis, cancer, and pregnancy. A set of projects focuses on safety of treatment with biologics. A series of pharmacogenetic studies explores tamoxifen treatment and breast cancer recurrence.
DCE, in a consortium with London School of Hygiene and Tropical Medicine, University College London, and Leiden University Medical Center, provides research services directly commissioned by the EMA in the area of pharmacoepidemiology and pharmacovigilance.
Several projects have been completed in the area of antidiabetic drugs, oral contraceptives, and systemic antibiotics.
DCE is a proud member of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), launched by the EMA. The network aims to strengthen the monitoring of post-marketed medical products in Europe.
DCE represents academia in the ENCePP Steering Group in the 2017-2019 term.